A
lexandria Real Estate Equities, Inc. (NYSE: ARE), a pioneering owner, operator and developer of collaborative mega campuses in AAA life science innovation cluster locations, announced a 10-year lease with Vaxcyte, Inc., a clinical-stage biopharmaceutical company working to combat bacterial diseases. The lease covers 258,581 RSF at the Alexandria Center for Life Science – San Carlos mega campus in the San Francisco Bay Area, including new space and an extension of existing space.

    Vaxcyte has been an anchor tenant on the campus since its opening in 2021. This expansion solidifies the Alexandria Center as a flagship destination for life science innovation in the Mid-Peninsula region. The purpose-built mega campus offers best-in-class essential Labspace infrastructure, convenient access to Highway 101 and walkability to Caltrain, boutique shops and restaurants.

    The Alexandria Center features inspiring design and people-centered amenities, including cutting-edge conference spaces, an expansive courtyard, a contemporary eatery, an artisanal coffee bar and a fully equipped fitness center. These amenities are designed to enable tenants to recruit and retain top talent, advancing their mission-critical work.

    With 739,157 RSF in operation (97.4% occupied) and approximately 1.4 million RSF of future development opportunities as of September 30, 2024, the Alexandria Center is positioned to meet the evolving needs of leading life science companies.

    About Alexandria Real Estate Equities, Inc.

    Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class life science REIT making a positive impact on the world. As the pioneer of the life science real estate niche since 1994, Alexandria owns and operates collaborative mega campuses in AAA life science innovation cluster locations across North America.

    As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years.

    Alexandria provides strategic capital to transformative life science companies through its venture capital platform. The company's unique business model ensures a high-quality tenant base, resulting in higher occupancy levels, longer lease terms, higher rental income, higher returns and greater long-term asset value.

    Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include Alexandria's impact on its tenants' ability to recruit and retain top talent, the features and amenities of the Alexandria Center for Life Science – San Carlos mega campus, and Alexandria's ability to continue attracting life science companies.

    Actual results may differ materially from those contained in or implied by Alexandria's forward-looking statements due to various factors, including risks and uncertainties detailed in its filings with the Securities and Exchange Commission.